decrease the consequences of treatment. In this analysis, we summarize the program outcomes and provide an economic perspective on implementation and sustainability. The Bridge Program enrolls and assesses patients at the end of cancer treatment using a
Search Results
Stephenie Kennedy-Rea, Adrienne Duckworth, Amy Reasinger Allen, and Samaneh Kalirai
Karen Valdés-Díaz, Halbert Hernández-Negrín, Leonel Valdés-Leiva, Diana Martin-Oliva, and Dianelys Pedraza-González
Background: Comorbidity in elderly has made it difficult to manage when they are affected by aggressive non-Hodgkin's lymphoma. This has led to the historical achievement of poor outcomes, hence the analysis of the impact of comorbidity in this
Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen
outcome is related primarily to underlying biology or aggressive cytoreduction with or without hyperthermic intraperitoneal chemotherapy is still debated. The role of modern systemic chemotherapy and targeted therapy in early or advanced nonmucinous and
Alexandre Hikiji Watanabe, Connor Willis, Melissa Pavilack-Kirker, Clara Lam, Leah Park, Sandhya Mehta, Jackie Kwong, Anindit Chhibber, Hillevi Bauer, Sabrina Ilham, Diana Brixner, and David Stenehjem
in ongoing phase III clinical trials. This study aims to understand the prevalence, current treatment patterns and outcomes of HER2-low patients. Methods : This descriptive study analyzed data from a patient tumor registry in the Huntsman Cancer
Neal Andruska, Benjamin W. Fischer-Valuck, Ruben Carmona, Temitope Agabalogun, Randall J. Brenneman, Hiram A. Gay, Jeff M. Michalski, and Brian C. Baumann
BT + ADT Relative to EBRT Alone Given the significant potential selection bias for EBRT versus BT, IPTW was used to balance covariables that influenced both treatment allocation and outcomes, and weight-adjusted Cox regression was used to
Junji Lin, Santosh Gautam, Nan Hu, Debra Wertz, Gboyega Adeboyeje, and Sumesh Kachroo
) and patient-reported outcomes (PROs). This study describes patient characteristics, treatment patterns, HCRU and PROs for these pts in community oncology settings. Methods: Retrospective medical records data from adults diagnosed with eSCLC between 1
Alexandra K. Zaleta, Erica E. Fortune, Melissa F. Miller, Branlyn W. DeRosa, Joanne S. Buzaglo, Karen Hurley, Mitch Golant, Sara Goldberger, Bruce Rapkin, Lillie D. Shockney, Jemeille Ackourey, and Kelly A. Clark
Background: Despite recognition that patient perspectives should inform cancer care, validated measures that meaningfully capture the patient experience across the cancer continuum remain lacking. We developed Valued Outcomes in the Cancer
Christopher D'Avella, Peter Whooley, Emily Milano, Brian Egleston, Martin Edelman, James Helstrom, Kenneth Patrick, and Jessica Bauman
admissions. Fox Chase Cancer Center (FCCC) developed an urgent care center, the direct referral unit (DRU), in 2012. We sought to characterize the experience of the DRU and its impact on clinical outcomes and utilization. Methods: We abstracted data for
The Cancer Center Cessation Initiative Coordinating Center and Expert Advisory Panel
smokers at the time of diagnosis. 5 Although compelling data have shown that quitting smoking after a cancer diagnosis leads to better health and quality of life outcomes, a 2009 survey reported that only 38% of NCI Cancer Centers recorded smoking as a
Krisda H. Chaiyachati, Diana Krause, Jessica Sugalski, Evan M. Graboyes, and Lawrence N. Shulman
widened racial and income disparities in cancer treatment outcomes. 19 – 21 Although national organizations such as the National Academies of Sciences, Engineering, and Medicine have identified transportation insecurity as a key social risk factor, 22
